BioNTech's shares dip after posting lukewarm revenue guidance
BioNTech has forecast lackluster sales for 2025 despite ending last year on a relatively strong note, causing the drugmaker’s shares to slide about 2% on Monday. The Covid-19 vaccine maker said it expects total revenues ...
BioNTech has forecast lackluster sales for 2025 despite ending last year on a relatively strong note, causing the drugmaker’s shares to slide about 2% on Monday.
The Covid-19 vaccine maker said it expects total revenues ...
